Sanofi announced Monday the appointment of current Genzyme COO David Meeker to the role of CEO of Genzyme effective November 1. Meeker will report to Sanofi CEO Christopher A. Viehbacher, who will retain the position of chairman of Genzyme.
Under Meeker’s guidance, Genzyme will incorporate the rare disease business and multiple sclerosis franchise. Genzyme’s other divisions, including renal, biosurgery and oncology, have been integrated within the existing Sanofi portfolio.